Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.

摘要: SummaryBackground A low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet can ameliorate symptoms in adult irritable bowel syndrome (IBS) within 48 h. Aim To determine the efficacy of a FODMAP childhood IBS whether gut microbial composition and/or metabolic capacity are associated with its efficacy. Methods In double-blind, crossover trial, children Rome III completed 1-week baseline period. They then were randomised to or typical American (TACD), followed by 5-day washout period before crossing over other diet. GI assessed abdominal pain frequency being primary outcome. Baseline (16S rRNA sequencing) (PICRUSt) determined. Metagenomic biomarker discovery (LEfSe) compared Responders (≥50% decrease on only) vs. Nonresponders (no improvement during either intervention). Results Thirty-three study. Less occurred TACD [1.1 ± 0.2 (SEM) episodes/day 1.7 ± 0.4, P < 0.05]. Compared (1.4 ± 0.2), had fewer daily episodes (P < 0.01) but more (P < 0.01). enriched at taxa known greater saccharolytic (e.g. Bacteroides, Ruminococcaceae, Faecalibacterium prausnitzii) three Kyoto Encyclopedia Genes Genomes orthologues, which two relate carbohydrate metabolism. Conclusions In IBS, decreases frequency. Gut microbiome biomarkers may be efficacy. ClinicalTrials.gov identifier: NCT01339117.